Genetown

Found 87,006 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension

  5/23/2023

  TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.

• Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation

  5/23/2023

  Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.

• Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

  5/22/2023

  Enveric Biosciences, Inc. has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders.

• Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

  5/22/2023

  Rhythm Pharmaceuticals, Inc. announced a collaboration with Genpharm Services FZ LLC to commercialize IMCIVREE® in Gulf Cooperation Council countries, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman and Bahrain.

• Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

  5/22/2023

  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

• HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting

  5/22/2023

  HiberCell today announced dosing of the first patient in a Phase 1b clinical trial investigating the effects of odetiglucan, a first-in-class immunomodulatory agent, in combination with the CD40 agonistic monoclonal antibody, CDX-1140, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the maintenance setting.

• Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer

  5/22/2023

  TellBio, Inc. announces publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who progress on endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibition.

• Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for LUMISIGHT™ Optical Imaging Agent for Breast Cancer

  5/22/2023

  Lumicell, Inc today announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for the LUMISIGHT™ Optical Imaging Agent and accepted the Premarket Approval (PMA) application for the Lumicell™ Direct Visualization System (DVS).

• FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

  5/22/2023

  Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM).

• Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians

  5/22/2023

  Microbot Medical Inc., the developer of the LIBERTY® Surgical Robotic System, the first single-use endovascular robotic system, announced a highly successful extended joint pre- clinical animal study held at a leading European-based research lab.

• Dana Farber Cancer Institute’s Jimmy Fund Celebrates 75 years of Progress and Impact on May 22

  5/22/2023

  Dana-Farber Cancer Institute’s Jimmy Fund will launch its 75th anniversary on Monday, May 22. Activities will include adult and pediatric patients unveiling and previewing the Jimmy Fund inspired cow, “Strong as Iron,” from this summer’s CowParade New England presented by Herb Chambers art installation.

• Gamida Cell Appoints Terry Coelho as CFO

  5/22/2023

  Gamida Cell Ltd. today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.

• Vesigen Highlights Therapeutic Platform for Non-Viral Delivery of Gene Editors and RNA at ASGCT 2023

  5/22/2023

  Vesigen Therapeutics, Inc showcased eight data presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting held May 16-20, 2023 in Los Angeles.

• Beta Bionics Announces FDA Clearance and Commercialization of the iLet Bionic Pancreas

  5/22/2023

  Beta Bionics, Inc. - a medical technology company focused on diabetes - announces FDA 510(k) clearance and the commercial launch of the iLet Bionic Pancreas.

• Corium's Novel ADHD Medication AZSTARYS® (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth Rate

  5/22/2023

  Corium, LLC announced that an analysis of a long-term, 12-month, open-label Phase 3 study of children aged 6-12 using its novel attention-deficit hyperactivity disorder (ADHD) medication AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) showed no clinically significant impact on weight and height growth rate in pediatric patients.

• TransCode Therapeutics Announces 1-for-20 Reverse Stock Split

  5/22/2023

  TransCode Therapeutics, Inc. today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023.

• Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

  5/22/2023

  Kymera Therapeutics, Inc. today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

• Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

  5/22/2023

  Centessa Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or without inhibitors. 

• Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference

  5/22/2023

  Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today presented new clinical data from its Phase 1 clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor, at the American Thoracic Society (ATS) International Conference in Washington, DC.